Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

Research output: Contribution to journalReviewResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{c218397d0cf24cd59e60cf75c2dac5f6,
title = "The efficacy and safety of exenatide once weekly in patients with type 2 diabetes",
abstract = "INTRODUCTION: Exenatide once weekly (QW) is a glucagon-like peptide 1 receptor agonist (GLP-1RA) that was approved in 2012 in Europe and the U.S.A. for the treatment of type 2 diabetes (T2D). Areas covered: This review provides an overview of the safety and efficacy of exenatide QW for the treatment of T2D and evaluates the benefit-risk ratio compared to other available long-acting GLP-1RAs. In addition, the authors provide an outline of the novel formulations and delivery methods of exenatide. Expert opinion: Exenatide QW is an efficacious and safe treatment for T2D. However, head-to-head trials have demonstrated exenatide QW to be inferior to liraglutide and semaglutide with respect to effects on fasting plasma glucose, glycated hemoglobin A1c, and bodyweight. In addition, exenatide QW appears inferior to liraglutide and semaglutide in terms of cardiovascular risk reduction. Currently, the overall risk-benefit profiles for the range of GLP-1RAs point to liraglutide and semaglutide as first-choice for the management of T2D, which has been confirmed by a recently published consensus report on the treatment of T2D from the American Diabetes Association and the European Association for the Study of Diabetes. The pricing of exenatide QW will most likely be a key determinant for its place in the future management of T2D.",
keywords = "cardiovascular adverse events, Exenatide extended-release, exenatide QW, glucagon-like peptide 1, glucagon-like peptide 1 receptor agonist, glycaemic control, type 2 diabetes, Body Weight, Exenatide/therapeutic use, Humans, Animals, Diabetes Mellitus, Type 2/drug therapy, Glucagon-Like Peptides/therapeutic use, Glucagon-Like Peptide-1 Receptor/agonists, Glycated Hemoglobin A/metabolism, Hypoglycemic Agents/adverse effects, Liraglutide/therapeutic use",
author = "Heimb{\"u}rger, {Sebastian M} and Andreas Br{\o}nden and Johansen, {Nicklas J} and Dejgaard, {Thomas F} and Tina Vilsb{\o}ll and Knop, {Filip K}",
year = "2019",
doi = "10.1080/14656566.2019.1571040",
language = "English",
volume = "20",
pages = "501--510",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "5",

}

RIS

TY - JOUR

T1 - The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

AU - Heimbürger, Sebastian M

AU - Brønden, Andreas

AU - Johansen, Nicklas J

AU - Dejgaard, Thomas F

AU - Vilsbøll, Tina

AU - Knop, Filip K

PY - 2019

Y1 - 2019

N2 - INTRODUCTION: Exenatide once weekly (QW) is a glucagon-like peptide 1 receptor agonist (GLP-1RA) that was approved in 2012 in Europe and the U.S.A. for the treatment of type 2 diabetes (T2D). Areas covered: This review provides an overview of the safety and efficacy of exenatide QW for the treatment of T2D and evaluates the benefit-risk ratio compared to other available long-acting GLP-1RAs. In addition, the authors provide an outline of the novel formulations and delivery methods of exenatide. Expert opinion: Exenatide QW is an efficacious and safe treatment for T2D. However, head-to-head trials have demonstrated exenatide QW to be inferior to liraglutide and semaglutide with respect to effects on fasting plasma glucose, glycated hemoglobin A1c, and bodyweight. In addition, exenatide QW appears inferior to liraglutide and semaglutide in terms of cardiovascular risk reduction. Currently, the overall risk-benefit profiles for the range of GLP-1RAs point to liraglutide and semaglutide as first-choice for the management of T2D, which has been confirmed by a recently published consensus report on the treatment of T2D from the American Diabetes Association and the European Association for the Study of Diabetes. The pricing of exenatide QW will most likely be a key determinant for its place in the future management of T2D.

AB - INTRODUCTION: Exenatide once weekly (QW) is a glucagon-like peptide 1 receptor agonist (GLP-1RA) that was approved in 2012 in Europe and the U.S.A. for the treatment of type 2 diabetes (T2D). Areas covered: This review provides an overview of the safety and efficacy of exenatide QW for the treatment of T2D and evaluates the benefit-risk ratio compared to other available long-acting GLP-1RAs. In addition, the authors provide an outline of the novel formulations and delivery methods of exenatide. Expert opinion: Exenatide QW is an efficacious and safe treatment for T2D. However, head-to-head trials have demonstrated exenatide QW to be inferior to liraglutide and semaglutide with respect to effects on fasting plasma glucose, glycated hemoglobin A1c, and bodyweight. In addition, exenatide QW appears inferior to liraglutide and semaglutide in terms of cardiovascular risk reduction. Currently, the overall risk-benefit profiles for the range of GLP-1RAs point to liraglutide and semaglutide as first-choice for the management of T2D, which has been confirmed by a recently published consensus report on the treatment of T2D from the American Diabetes Association and the European Association for the Study of Diabetes. The pricing of exenatide QW will most likely be a key determinant for its place in the future management of T2D.

KW - cardiovascular adverse events

KW - Exenatide extended-release

KW - exenatide QW

KW - glucagon-like peptide 1

KW - glucagon-like peptide 1 receptor agonist

KW - glycaemic control

KW - type 2 diabetes

KW - Body Weight

KW - Exenatide/therapeutic use

KW - Humans

KW - Animals

KW - Diabetes Mellitus, Type 2/drug therapy

KW - Glucagon-Like Peptides/therapeutic use

KW - Glucagon-Like Peptide-1 Receptor/agonists

KW - Glycated Hemoglobin A/metabolism

KW - Hypoglycemic Agents/adverse effects

KW - Liraglutide/therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=85061310944&partnerID=8YFLogxK

U2 - 10.1080/14656566.2019.1571040

DO - 10.1080/14656566.2019.1571040

M3 - Review

VL - 20

SP - 501

EP - 510

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -

ID: 56500407